- Michael Smith Laboratories
- Department of Medical Genetics
- Department of Microbiology and Immunology
- Department of Urologic Sciences, Associate Member
- Vancouver Prostate Centre, Senior Scientist
- Centre for Blood Research, Member
- Djavad Mowafaghian Centre for Brain Health, Member
- Genome Sciences and Technology (GSAT) Graduate Program, Program Supervisor
- PDF, Ludwig Institute for Cancer Research, Karolinska Institute 1989
- PDF, Institut Suisse de Recherches Expérimentales sur le Cancer, EPFL, Lausanne 1987
- D.Phil., Molecular Immunology and Pathology, University of Oxford, 1985
- B.Sc., Biochemistry, University of Victoria, 1981
Dr. Wilfred A. Jefferies earned his Doctor of Philosophy degree from the Sir William Dunn School of Pathology at the University of Oxford for studies on glycoproteins expressed on activated lymphocytes. His discoveries include identifying the OX40 (CD134) co-stimulatory immune checkpoint molecule expressed on activated CD4 cells. He defined transferrin receptors (OX26/CD71) in the Blood-Brain Barrier and characterized diseases of the central nervous system in which hypervascularity occurs. From these observations, Dr. Jefferies created the p97/melanotransferrin “Trojan Horse” for delivering therapeutics to the brain for the treatment of brain tumours. Further work includes elucidating immune subversion mechanisms in viruses and tumours, along with methods to overcome these conditions, and characterizing the epigenetic regulation of antigen processing in cancer cells. Dr. Jefferies’ research group recently discovered the CD74-dependent Major Histocompatibility Complex-I (MHC-I or HLA) and the MHC-I recycling intracellular pathways underpinning cross-presentation in dendritic cells, both of which are critical for priming MHC-I restricted immune responses against viruses and tumours. Finally, his group has recently identified two important classes of calcium channels that function to limit inappropriate immune responses, leading to pathology in autoimmune disease and possibly cancer.
Dr. Jefferies’ current research program focuses on discovering and translating new therapies for disease. His current interests are in tumour immunology and cancer immunotherapy; antigen presentation and vaccines; and blood-brain barrier and angiogenesis. His work on cancer targets the restoration of the immune system’s ability to recognize tumours that have lost functional antigen processing machinery components, which may render selected tumours “invisible” to adaptive immune responses. His team is also utilizing novel screening systems to identify genes, proteins and small molecules that are able to restore and enhance immune recognition and killing of cancer cells. Notably, with other Vancouver Prostate Centre colleagues, Dr. Jefferies is leading an initiative to examine the use of IL-33 as an immune-biomarker for metastatic prostate tumours and a prognosticator for recurrence of prostate cancer in patients.
Dr. Jefferies has more than 100 publications, holds 60 patents, and has supervised 42 graduate students, 17 postdoctoral fellows and over 100 undergraduate research projects. His research discoveries have created the intellectual foundation for four University spin-out companies, representing a critical avenue for knowledge translation resulting in hundreds of full-time high technology positions. Overall, Dr. Jefferies’ research continues to contribute to understanding how immune responses are initiated and expanded, how tumours and infectious pathogens subvert these processes, and how autoimmunity results from dysregulation of the immune response.
Biochemistry, biotechnology, bioinformatics, biological imaging, genomics, immunology, translation, systems biology, bioengineering, biomolecular engineering, drug discovery, enzymology, evolution, infectious disease, personalized medicine, proteomics, synthetic biology, gene/cell therapy systems, bioproducts, cell delivery, epigenomics, microbial pathogenesis, regenerative medicine, carcinogenesis, gene editing, neurobiology, science education, drug delivery, natural products, pharmacology